Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.99
NAS:ACOR's Cash-to-Debt is ranked lower than
82% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NAS:ACOR: 0.99 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACOR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: 14.27 Max: 83.08
Current: 0.99
0.41
83.08
Equity-to-Asset 0.46
NAS:ACOR's Equity-to-Asset is ranked lower than
76% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ACOR: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ACOR' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.98  Med: 0.51 Max: 0.75
Current: 0.46
-3.98
0.75
Debt-to-Equity 0.61
NAS:ACOR's Debt-to-Equity is ranked lower than
74% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ACOR: 0.61 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ACOR' s Debt-to-Equity Range Over the Past 10 Years
Min: -64.73  Med: 0.05 Max: 0.64
Current: 0.61
-64.73
0.64
Debt-to-EBITDA -1.73
NAS:ACOR's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. NAS:ACOR: -1.73 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ACOR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -79.6  Med: 0.01 Max: 6.36
Current: -1.73
-79.6
6.36
Interest Coverage 5.48
NAS:ACOR's Interest Coverage is ranked lower than
99.99% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ACOR: 5.48 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ACOR' s Interest Coverage Range Over the Past 10 Years
Min: 2.9  Med: 7.72 Max: 13.99
Current: 5.48
2.9
13.99
Piotroski F-Score: 4
Altman Z-Score: 1.00
Beneish M-Score: -2.67
WACC vs ROIC
14.29%
13.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 19.09
NAS:ACOR's Operating Margin % is ranked higher than
58% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NAS:ACOR: 19.09 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ACOR' s Operating Margin % Range Over the Past 10 Years
Min: -153.55  Med: 8.7 Max: 19.09
Current: 19.09
-153.55
19.09
Net Margin % -36.98
NAS:ACOR's Net Margin % is ranked higher than
58% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NAS:ACOR: -36.98 )
Ranked among companies with meaningful Net Margin % only.
NAS:ACOR' s Net Margin % Range Over the Past 10 Years
Min: -155.44  Med: -1.96 Max: 50.67
Current: -36.98
-155.44
50.67
ROE % -34.13
NAS:ACOR's ROE % is ranked higher than
53% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NAS:ACOR: -34.13 )
Ranked among companies with meaningful ROE % only.
NAS:ACOR' s ROE % Range Over the Past 10 Years
Min: -54.95  Med: -1.77 Max: 52.43
Current: -34.13
-54.95
52.43
ROA % -16.66
NAS:ACOR's ROA % is ranked higher than
62% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NAS:ACOR: -16.66 )
Ranked among companies with meaningful ROA % only.
NAS:ACOR' s ROA % Range Over the Past 10 Years
Min: -36.37  Med: -0.9 Max: 32.8
Current: -16.66
-36.37
32.8
ROC (Joel Greenblatt) % -551.74
NAS:ACOR's ROC (Joel Greenblatt) % is ranked lower than
54% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NAS:ACOR: -551.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACOR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4354.61  Med: 5.75 Max: 1008.02
Current: -551.74
-4354.61
1008.02
3-Year Revenue Growth Rate 10.70
NAS:ACOR's 3-Year Revenue Growth Rate is ranked higher than
61% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NAS:ACOR: 10.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ACOR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.8  Med: 11.6 Max: 73.6
Current: 10.7
-61.8
73.6
GuruFocus has detected 4 Warning Signs with Acorda Therapeutics Inc NAS:ACOR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACOR's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ACOR Guru Trades in Q2 2017

Steven Cohen 40,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt 83,673 sh (-35.35%)
» More
Q3 2017

ACOR Guru Trades in Q3 2017

Leucadia National 13,392 sh (New)
Joel Greenblatt 153,742 sh (+83.74%)
» More
Q4 2017

ACOR Guru Trades in Q4 2017

Paul Tudor Jones 16,886 sh (New)
Diamond Hill Capital 18,702 sh (New)
Leucadia National 13,392 sh (unchged)
Joel Greenblatt 43,945 sh (-71.42%)
» More
Q1 2018

ACOR Guru Trades in Q1 2018

John Hussman 50,000 sh (New)
Chuck Royce 402 sh (New)
Jim Simons 207,500 sh (New)
Joel Greenblatt 51,048 sh (+16.16%)
Leucadia National Sold Out
Paul Tudor Jones Sold Out
Diamond Hill Capital 13,774 sh (-26.35%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-03-31 Add 16.16%$21.05 - $27.8 $ 30.0020%51,048
Leucadia National 2018-03-31 Sold Out 0.02%$21.05 - $27.8 $ 30.0020%0
Joel Greenblatt 2017-12-31 Reduce -71.42%0.04%$17 - $28.65 $ 30.0026%43,945
Joel Greenblatt 2017-09-30 Add 83.74%0.02%$19.45 - $25.7 $ 30.0037%153,742
Leucadia National 2017-09-30 New Buy0.03%$19.45 - $25.7 $ 30.0037%13,392
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:TSXV:CRON, SHSE:603896, NYSE:BHVN, NYSE:CO, SZSE:002022, NAS:TGTX, NAS:DVAX, SAU:2070, SZSE:002872, NAS:RVNC, SZSE:300204, NAS:CTMX, NAS:ATNX, NAS:PTCT, XMCE:ROVI, OSTO:HMED, SHSE:603718, XKRX:003000, ASX:SRX, XKRX:005690 » details
Traded in other countries:CDG.Germany,
Headquarter Location:USA
Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development & commercialization of novel therapies for the treatment of neurological disorders.

Acorda Therapeutics is a biotechnology company that identifies, develops, and commercializes novel therapies for neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

Top Ranked Articles about Acorda Therapeutics Inc

Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACOR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ACOR
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acorda Therapeutics, Inc. Shareholders
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Acorda Therapeutics, Inc. - ACOR
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018
ACOR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 – ACOR

Ratios

vs
industry
vs
history
PB Ratio 2.57
ACOR's PB Ratio is ranked higher than
74% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ACOR: 2.57 )
Ranked among companies with meaningful PB Ratio only.
ACOR' s PB Ratio Range Over the Past 10 Years
Min: 0.99  Med: 3.4 Max: 12.1
Current: 2.57
0.99
12.1
PS Ratio 2.41
ACOR's PS Ratio is ranked higher than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 2.41 )
Ranked among companies with meaningful PS Ratio only.
ACOR' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 3.83 Max: 24.45
Current: 2.41
1.24
24.45
Price-to-Free-Cash-Flow 10.10
ACOR's Price-to-Free-Cash-Flow is ranked higher than
73% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. ACOR: 10.10 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACOR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.66  Med: 29.35 Max: 125.28
Current: 10.1
7.66
125.28
Price-to-Operating-Cash-Flow 9.20
ACOR's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. ACOR: 9.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACOR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 26.47 Max: 380.41
Current: 9.2
6.98
380.41
EV-to-EBIT -6.53
ACOR's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. ACOR: -6.53 )
Ranked among companies with meaningful EV-to-EBIT only.
ACOR' s EV-to-EBIT Range Over the Past 10 Years
Min: -111.4  Med: 13.7 Max: 201.3
Current: -6.53
-111.4
201.3
EV-to-EBITDA -7.24
ACOR's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. ACOR: -7.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -322.1  Med: 16 Max: 188.3
Current: -7.24
-322.1
188.3
EV-to-Revenue 2.47
ACOR's EV-to-Revenue is ranked higher than
89% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. ACOR: 2.47 )
Ranked among companies with meaningful EV-to-Revenue only.
ACOR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.2 Max: 22.1
Current: 2.47
1.6
22.1
Current Ratio 3.65
ACOR's Current Ratio is ranked lower than
61% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ACOR: 3.65 )
Ranked among companies with meaningful Current Ratio only.
ACOR' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 3.61 Max: 8.36
Current: 3.65
0.59
8.36
Quick Ratio 3.41
ACOR's Quick Ratio is ranked lower than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. ACOR: 3.41 )
Ranked among companies with meaningful Quick Ratio only.
ACOR' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.35 Max: 8.09
Current: 3.41
0.42
8.09
Days Inventory 108.07
ACOR's Days Inventory is ranked higher than
56% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. ACOR: 108.07 )
Ranked among companies with meaningful Days Inventory only.
ACOR' s Days Inventory Range Over the Past 10 Years
Min: 108.07  Med: 145.3 Max: 228.57
Current: 108.07
108.07
228.57
Days Sales Outstanding 32.24
ACOR's Days Sales Outstanding is ranked higher than
62% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. ACOR: 32.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.31  Med: 34.34 Max: 50.51
Current: 32.24
23.31
50.51
Days Payable 50.92
ACOR's Days Payable is ranked higher than
54% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. ACOR: 50.92 )
Ranked among companies with meaningful Days Payable only.
ACOR' s Days Payable Range Over the Past 10 Years
Min: 50.92  Med: 104.12 Max: 383.28
Current: 50.92
50.92
383.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.50
ACOR's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ACOR: -3.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACOR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -469.7  Med: -3.65 Max: -1.4
Current: -3.5
-469.7
-1.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.38
ACOR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. ACOR: 1.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACOR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.82  Med: 1.77 Max: 22.28
Current: 1.38
0.82
22.28
Price-to-Median-PS-Value 0.63
ACOR's Price-to-Median-PS-Value is ranked higher than
82% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ACOR: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACOR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.04 Max: 5.73
Current: 0.63
0.08
5.73
Earnings Yield (Greenblatt) % -15.31
ACOR's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. ACOR: -15.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACOR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.6  Med: 0.5 Max: 7.7
Current: -15.31
-23.6
7.7
Forward Rate of Return (Yacktman) % 7.01
ACOR's Forward Rate of Return (Yacktman) % is ranked lower than
62% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. ACOR: 7.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACOR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -121.3  Med: 0.2 Max: 14.4
Current: 7.01
-121.3
14.4

More Statistics

Revenue (TTM) (Mil) $575.07
EPS (TTM) $ -4.63
Beta2.28
Volatility42.45%
52-Week Range $16.55 - 36.35
Shares Outstanding (Mil)47.07

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 340 274 284
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.01 -1.19 -0.64
EPS without NRI ($) -1.01 -1.19 -0.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}